FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2586049513> ?p ?o ?g. }

• W2586049513 endingPage "46564" @default.
• W2586049513 startingPage "46557" @default.
• W2586049513 abstract "// Birgit E.P. Vriens 1 , Kristien B.M. Keymeulen 2 , Judith R. Kroep 3 , Ayoub Charehbili 3,4 , Petronella G. Peer 5 , Maaike de Boer 1 , Maureen J.B. Aarts 1 , Esther M. Heuts 2 , Vivianne C.G. Tjan-Heijnen 1 , The Dutch Breast Cancer Research Group (BOOG) 1 Department of Medical Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands 2 Department of Surgery, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands 3 Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands 4 Department of Surgery, Leiden University Medical Center, Nijmegen, The Netherlands 5 Biostatistics, Radboud Institute for Health Sciences, Nijmegen, The Netherlands Correspondence to: Vivianne C.G. Tjan-Heijnen, email: // Keywords : breast cancer, neoadjuvant chemotherapy, sentinel node procedure, node-negative Received : July 25, 2016 Accepted : January 23, 2017 Published : February 04, 2017 Abstract Background: Primary aim of our study was to assess the impact of timing of sentinel node procedure, pre- versus post-neoadjuvant chemotherapy, on final pathologic node-negative rate (pN0) in patients with clinically node-negative (cN0) breast cancer. Secondary endpoint was the usability of the sentinel node procedure in patients with clinically node-positive disease that converted to cN0 after neoadjuvant chemotherapy. Patients and Methods: Patients were enrolled in two sequentially conducted Dutch phase III trials, studying the impact of two neoadjuvant chemotherapy schedules and use of zoledronic acid on complete pathologic response rate. For the present analyses, patients were excluded if they had not undergone surgical axillary staging. Results: In total 439 patients were included, of whom 230 (52%) had pre-treatment cN0. In this group, pN0 status was seen in 58% ( N = 23) of patients with a sentinel node biopsy post-neoadjuvant chemotherapy compared to 51% ( N = 83) pre-neoadjuvant chemotherapy, including the axillary lymph node dissection whenever performed. In multivariable analysis, timing of sentinel node procedure (pre- versus post- neoadjuvant chemotherapy) was, however, not significantly associated with final pN0/pN0(i+) status, with an odds ratio of 1.18 (95% CI 0.64 - 2.18) after correction for age, clinical tumor status, histology, grade, hormone- and HER2 receptor. Of patients with clinically node-positive disease only 15% had a final pN0 status, with a false-negative rate of the sentinel node of 30%. Conclusion: In breast cancer patients with cN0 disease, sentinel node procedure performed post-neoadjuvant chemotherapy led to nodal down staging, although not statistically significant after multivariate correction for patient and tumor characteristics." @default.
• W2586049513 created "2017-02-17" @default.
• W2586049513 creator A5015398820 @default.
• W2586049513 creator A5021122880 @default.
• W2586049513 creator A5023734176 @default.
• W2586049513 creator A5054754505 @default.
• W2586049513 creator A5059044768 @default.
• W2586049513 creator A5064077142 @default.
• W2586049513 creator A5071277621 @default.
• W2586049513 creator A5074930103 @default.
• W2586049513 creator A5081011064 @default.
• W2586049513 date "2017-02-04" @default.
• W2586049513 modified "2023-10-06" @default.
• W2586049513 title "Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies" @default.
• W2586049513 cites W1984107586 @default.
• W2586049513 cites W1991515788 @default.
• W2586049513 cites W2001069453 @default.
• W2586049513 cites W2006598098 @default.
• W2586049513 cites W2011683694 @default.
• W2586049513 cites W2012620884 @default.
• W2586049513 cites W2020991990 @default.
• W2586049513 cites W2034990993 @default.
• W2586049513 cites W2039486450 @default.
• W2586049513 cites W2103218083 @default.
• W2586049513 cites W2111329020 @default.
• W2586049513 cites W2130335800 @default.
• W2586049513 cites W2133865595 @default.
• W2586049513 cites W2157483882 @default.
• W2586049513 cites W2172114428 @default.
• W2586049513 cites W2214028082 @default.
• W2586049513 cites W2268087059 @default.
• W2586049513 doi "https://doi.org/10.18632/oncotarget.15101" @default.
• W2586049513 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5542292" @default.
• W2586049513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28177921" @default.
• W2586049513 hasPublicationYear "2017" @default.
• W2586049513 type Work @default.
• W2586049513 sameAs 2586049513 @default.
• W2586049513 citedByCount "5" @default.
• W2586049513 countsByYear W25860495132017 @default.
• W2586049513 countsByYear W25860495132020 @default.
• W2586049513 countsByYear W25860495132021 @default.
• W2586049513 countsByYear W25860495132023 @default.
• W2586049513 crossrefType "journal-article" @default.
• W2586049513 hasAuthorship W2586049513A5015398820 @default.
• W2586049513 hasAuthorship W2586049513A5021122880 @default.
• W2586049513 hasAuthorship W2586049513A5023734176 @default.
• W2586049513 hasAuthorship W2586049513A5054754505 @default.
• W2586049513 hasAuthorship W2586049513A5059044768 @default.
• W2586049513 hasAuthorship W2586049513A5064077142 @default.
• W2586049513 hasAuthorship W2586049513A5071277621 @default.
• W2586049513 hasAuthorship W2586049513A5074930103 @default.
• W2586049513 hasAuthorship W2586049513A5081011064 @default.
• W2586049513 hasBestOaLocation W25860495131 @default.
• W2586049513 hasConcept C121608353 @default.
• W2586049513 hasConcept C126322002 @default.
• W2586049513 hasConcept C143998085 @default.
• W2586049513 hasConcept C179671157 @default.
• W2586049513 hasConcept C203092338 @default.
• W2586049513 hasConcept C2776694085 @default.
• W2586049513 hasConcept C2778292576 @default.
• W2586049513 hasConcept C2780212769 @default.
• W2586049513 hasConcept C530470458 @default.
• W2586049513 hasConcept C535046627 @default.
• W2586049513 hasConcept C71924100 @default.
• W2586049513 hasConceptScore W2586049513C121608353 @default.
• W2586049513 hasConceptScore W2586049513C126322002 @default.
• W2586049513 hasConceptScore W2586049513C143998085 @default.
• W2586049513 hasConceptScore W2586049513C179671157 @default.
• W2586049513 hasConceptScore W2586049513C203092338 @default.
• W2586049513 hasConceptScore W2586049513C2776694085 @default.
• W2586049513 hasConceptScore W2586049513C2778292576 @default.
• W2586049513 hasConceptScore W2586049513C2780212769 @default.
• W2586049513 hasConceptScore W2586049513C530470458 @default.
• W2586049513 hasConceptScore W2586049513C535046627 @default.
• W2586049513 hasConceptScore W2586049513C71924100 @default.
• W2586049513 hasIssue "28" @default.
• W2586049513 hasLocation W25860495131 @default.
• W2586049513 hasLocation W25860495132 @default.
• W2586049513 hasLocation W25860495133 @default.
• W2586049513 hasLocation W25860495134 @default.
• W2586049513 hasOpenAccess W2586049513 @default.
• W2586049513 hasPrimaryLocation W25860495131 @default.
• W2586049513 hasRelatedWork W1255356622 @default.
• W2586049513 hasRelatedWork W2161568138 @default.
• W2586049513 hasRelatedWork W2358701816 @default.
• W2586049513 hasRelatedWork W2367105124 @default.
• W2586049513 hasRelatedWork W2371347765 @default.
• W2586049513 hasRelatedWork W2390548009 @default.
• W2586049513 hasRelatedWork W2391322037 @default.
• W2586049513 hasRelatedWork W2559834580 @default.
• W2586049513 hasRelatedWork W3089077900 @default.
• W2586049513 hasRelatedWork W3092055942 @default.
• W2586049513 hasVolume "8" @default.
• W2586049513 isParatext "false" @default.
• W2586049513 isRetracted "false" @default.
• W2586049513 magId "2586049513" @default.
• W2586049513 workType "article" @default.